Novo Nordisk has launched a share repurchase program to buy back B shares worth up to DKK 11.2 billion from May 2026 to February 2027, as part of a larger DKK 15 billion buyback plan starting February 2026. Since February, the company has repurchased over 25.9 million B shares at an average price of DKK 276.33 per share, totaling about DKK 7.16 billion. This buyback reduces the number of shares in circulation, potentially increasing shareholder value. Novo Nordisk continues to strengthen its financial position while focusing on its mission to combat chronic diseases globally.
Deutsche Bank downgraded Novo Nordisk shares from 'hold' to 'sell', cutting the target price by 9% due to concerns over midterm growth and pipeline setbacks. The downgrade follows a mixed Q2 update and highlights worries about limited Medicare prescr...
In Q2 2026, Eli Lilly reported a strong 48% revenue growth driven by blockbuster obesity drugs Mounjaro and Zepbound, especially with rapid international expansion. Novo Nordisk faced challenges including shrinking U.S. sales, price cuts, layoffs, an...
Eli Lilly has introduced Foundayo, an oral GLP-1 pill for weight loss and type 2 diabetes, in UK pharmacies following recent approval. This tablet offers a convenient alternative to injections and is licensed for adults with certain BMI criteria or w...
Novo Nordisk's stock appears to have formed a long-term bottom as its turnaround gains momentum, with losses in market share to Eli Lilly stabilizing. Trading at just over 15 times forward earnings, the stock is valued at about half of Eli Lilly's mu...
